SEMAX Research:
Nootropic Peptide & ACTH Analogue
SEMAX is a synthetic heptapeptide derived from the ACTH(4-7) sequence, engineered for extended CNS activity. It has been extensively studied for neuroprotective, nootropic, and stroke recovery applications, with a documented BDNF-upregulating mechanism of action.
What Is SEMAX?
SEMAX (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is based on the ACTH(4-7) tetrapeptide core (Met-Glu-His-Phe), which is responsible for the neurotrophic (but not corticotropic) activity of ACTH, extended with a Pro-Gly-Pro sequence to confer metabolic stability and facilitate CNS penetration.
SEMAX has been registered as a nootropic and neuroprotective drug in Russia and has an extensive research history spanning stroke recovery, ischemic brain injury, Alzheimer’s disease models, and cognitive enhancement studies. It does not bind ACTH/MC receptors at significant affinity, avoiding the adrenocortical effects of native ACTH. Lumen Peppers provides research-grade SEMAX for laboratory investigation.
Key Research Findings
Stroke Recovery Models
SEMAX is one of the most-studied neuropeptides in ischemic stroke models. Rodent MCAO (middle cerebral artery occlusion) studies show reduced infarct volume, improved neurological scores, and enhanced behavioral recovery with post-ischemia SEMAX administration.
BDNF Upregulation
SEMAX produces the strongest documented BDNF upregulation of any synthetic peptide in rat hippocampal and cortical studies — BDNF mRNA increases of 300–600% have been reported. This is proposed as the primary mechanism for observed neuroprotective and cognitive effects.
Cognitive Enhancement
Spatial and non-spatial memory tasks in rodent models show SEMAX improves acquisition speed, retention, and recall. These effects are observed in both normal animals and models of cognitive impairment (aging, hypoxia, ischemia).
Neuroprotection
Semax protects neurons against excitotoxic (glutamate), oxidative (H₂O₂), and ischemic insults in cell culture and animal models. Proposed mechanisms include BDNF/TrkB activation, reduction of pro-apoptotic signaling, and mitochondrial protection.
Dopamine & Serotonin Modulation
Microdialysis studies show SEMAX elevates extracellular dopamine in the striatum and prefrontal cortex, and modulates serotonin turnover in limbic regions — neurochemical changes consistent with observed cognitive and mood-related effects.
Optic Nerve Research
Studies in optic nerve ischemia models show SEMAX protects retinal ganglion cells and preserves visual function. This peripheral neuroprotective effect may extend the compound's research utility beyond CNS applications.
Proposed Mechanisms of Action
SEMAX strongly upregulates BDNF transcription in hippocampal and cortical neurons. BDNF binds TrkB receptors, activating MAPK/ERK (synaptic strengthening) and PI3K/Akt (neuronal survival) pathways — the primary proposed mechanism for cognitive and neuroprotective effects.
In addition to BDNF, SEMAX upregulates NGF (nerve growth factor) in basal forebrain cholinergic neurons and VEGF in ischemic brain tissue, promoting both neurotrophic support and post-ischemic angiogenesis.
SEMAX increases dopamine synthesis and release in striatum and prefrontal cortex via unclear upstream mechanisms. This dopaminergic enhancement may underlie observed improvements in working memory, attention, and motivation in rodent behavioral tests.
SEMAX activates Bcl-2 family protein upregulation (anti-apoptotic) and reduces cytochrome c release from mitochondria in ischemic neuron models. Caspase-3 activation is attenuated, increasing neuronal survival following excitotoxic or ischemic insults.
Post-ischemia models show SEMAX reduces microglia activation, decreases pro-inflammatory cytokine (IL-1β, TNF-α) expression in brain tissue, and promotes transition toward anti-inflammatory M2 microglial phenotypes.
Active Research Applications
Stroke & Ischemia
MCAO and global ischemia rodent models examining SEMAX's effects on infarct volume, neurological score, behavioral recovery, and BDNF/VEGF expression.
Cognitive Research
Spatial and non-spatial learning assays in normal and cognitively impaired rodent models, with gene expression and LTP electrophysiology readouts.
Neurodegeneration
Alzheimer's (APP/PS1 mice), Parkinson's (6-OHDA), and ALS models examining SEMAX neuroprotective effects and neurotrophic factor induction.
Optic Nerve Models
Optic nerve ischemia and glaucoma models examining retinal ganglion cell protection with topical or systemic SEMAX application.
Drug Delivery Research
Intranasal absorption, CNS bioavailability, and pharmacokinetic studies comparing nasal spray vs. SC routes — critical for understanding optimal delivery in rodent models.
Neurotransmitter Studies
In vivo microdialysis measuring dopamine, serotonin, and noradrenaline in prefrontal cortex and striatum following SEMAX administration.
SEMAX vs. SELANK
SEMAX and SELANK are the two most studied synthetic peptide nootropics from Russian research, often compared in preclinical behavioral and neurochemical studies.
SEMAX
SELANK
Protocol Notes for Researchers
SEMAX — Research Grade ≥99% Purity
Research-grade purity ≥99% · Third-party HPLC verified · Ships from the U.S.
All products sold by Lumen Peppers are intended exclusively for in vitro laboratory research and investigative purposes. These compounds are not approved by the FDA for human or veterinary use. They are not drugs, supplements, or medications. Lumen Peppers makes no therapeutic claims. Researchers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.